Inhibrx reported an early clinical win for its OX40 agonist, with response signals in head and neck cancer. The company framed the strongest results in a smaller subset of patients with HPV-positive tumors, limiting how broadly the therapy may apply. OX40 has historically been a challenging immune-oncology target, with multiple drug developers having attempted and missed in earlier programs. Inhibrx positioned the new data as a first meaningful step toward better patient selection and combination strategies, including potential pairing with cancer vaccines. Management commentary emphasized “durability” based on progression-free survival, setting up the next phase of development to confirm benefit and define the target population more precisely.